Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2024 Filed Aug 28, 2024 23:45 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015816 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,466 Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:44 UTC |
SCHWARTZ ALICE N10% owner · Director Emeritus
|
GiftBio-Rad B Common Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015814 · form4.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · 10% owner · Director Emeritus 10b5-1 filing: No plan indicated Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 437,510 Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:44 UTC |
SCHWARTZ ALICE N10% owner · Director Emeritus
|
GiftBio-Rad A Common Stock | 3,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015814 · form4.xml · nonDerivative · entry 1 SCHWARTZ ALICE N · CIK 0001248076 · 10% owner · Director Emeritus 10b5-1 filing: No plan indicated Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 1,781,356 Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 20:04 UTC |
ENGELHARDT EVA ANETTEEVP, President, CDG
|
GrantRestricted Stock Units · Derivative | 983 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-014126 · form4.xml · derivative · entry 1 ENGELHARDT EVA ANETTE · CIK 0002024911 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 983 Underlying: Bio-Rad A Common Stock · 983 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 17:42 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 369 | $281.91 | $104,023.46 |
DisclosureSEC source: 0001062993-24-012628 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,573 Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 357 | $277.11 | $98,928.27 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,719.8881 Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 21:53 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009082 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,076.8881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 9.7660 and 27.5220 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2023 and 03/31/2024, respectively. Read SEC document |
| April 24, 2024 Filed Apr 29, 2024 22:17 UTC |
Lakkaraju Roop KalyanEVP, Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 4,311 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009019 · form4.xml · derivative · entry 1 Lakkaraju Roop Kalyan · CIK 0001396867 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,311 Underlying: Bio-Rad A Common Stock · 4,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| April 24, 2024 Filed Apr 29, 2024 22:12 UTC |
ENLOE COURTNEY CEVP, General Counsel & Sec
|
GrantRestricted Stock Units · Derivative | 744 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009013 · form4.xml · derivative · entry 1 ENLOE COURTNEY C · CIK 0002019843 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744 Underlying: Bio-Rad A Common Stock · 744 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:29 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,891 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006221 · form4.xml · derivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,891 Underlying: Bio-Rad A Common Stock · 5,891 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:28 UTC |
MAY SIMONEVP, President, LSG
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,535 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006220 · form4.xml · derivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,535 Underlying: Bio-Rad A Common Stock · 3,535 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:28 UTC |
COREY COLLEENEVP, Global Human Resources
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,357 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006219 · form4.xml · derivative · entry 1 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,357 Underlying: Bio-Rad A Common Stock · 2,357 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:28 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,357 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006218 · form4.xml · derivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,357 Underlying: Bio-Rad A Common Stock · 2,357 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:27 UTC |
EVRAN SEDATEVP, Global Supply Chain
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,535 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006217 · form4.xml · derivative · entry 2 EVRAN SEDAT · CIK 0001993147 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,535 Underlying: Bio-Rad A Common Stock · 3,535 shares Expires 2034-03-08 F2 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:23 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,137 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006216 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,137 Underlying: Bio-Rad A Common Stock · 14,137 shares Expires 2034-03-08 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:22 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,535 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006215 · form4.xml · derivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,535 Underlying: Bio-Rad A Common Stock · 3,535 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:24 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001062993-24-004959 · form4.xml · derivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 2,500 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:24 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 2,500 | $330.55 | $826,375.00 |
DisclosureSEC source: 0001062993-24-004959 · form4.xml · nonDerivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,397.4775 Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 22:24 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionBio-Rad A Common Stock | 2,500 | $326.15 | $815,375.00 |
DisclosureSEC source: 0001062993-24-004959 · form4.xml · nonDerivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,897.4775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13.6810 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/29/2023. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 23:38 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001062993-24-004835 · form4.xml · derivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 23:38 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 3,000 | $336.00 | $1,008,000.00 |
DisclosureSEC source: 0001062993-24-004835 · form4.xml · nonDerivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.53 to $336.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 23:38 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionBio-Rad A Common Stock | 3,000 | $215.98 | $647,940.00 |
DisclosureSEC source: 0001062993-24-004835 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 17:19 UTC |
WRIGHT DARAEVP, President, CDG
|
Exercise / conversionRestricted Stock Units · Derivative | 502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022819 · form4.xml · derivative · entry 3 WRIGHT DARA · CIK 0001796980 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503 Underlying: Bio-Rad A Common Stock · 502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 17:19 UTC |
WRIGHT DARAEVP, President, CDG
|
Tax withholdingBio-Rad A Common Stock | 174 | $306.12 | $53,264.88 |
DisclosureSEC source: 0001062993-23-022819 · form4.xml · nonDerivative · entry 2 WRIGHT DARA · CIK 0001796980 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,827.0776 Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 17:19 UTC |
WRIGHT DARAEVP, President, CDG
|
Exercise / conversionBio-Rad A Common Stock | 502 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022819 · form4.xml · nonDerivative · entry 1 WRIGHT DARA · CIK 0001796980 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,001.0776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 00:43 UTC |
WRIGHT DARAEVP, President, CDG
|
SaleBio-Rad A Common Stock | 1,200 | $299.16 | $358,992.00 |
DisclosureSEC source: 0001062993-23-022476 · form4.xml · nonDerivative · entry 1 WRIGHT DARA · CIK 0001796980 · EVP, President, CDG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,499.0776 F1 · balance_after: Includes 17.2030 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/29/2023. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:14 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022114 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 12,949 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:14 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022114 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,409 Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:26 UTC |
SCHWARTZ ALICE N10% owner · Director Emeritus
|
GiftBio-Rad B Common Stock | 294 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022075 · form4.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · 10% owner · Director Emeritus 10b5-1 filing: No plan indicated Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 437,852 Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:26 UTC |
SCHWARTZ ALICE N10% owner · Director Emeritus
|
GiftBio-Rad A Common Stock | 3,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022075 · form4.xml · nonDerivative · entry 1 SCHWARTZ ALICE N · CIK 0001248076 · 10% owner · Director Emeritus 10b5-1 filing: No plan indicated Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 1,784,546 Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 19:33 UTC |
Allison SchwartzDirector
|
GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022193 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,939 Read SEC document |
| December 05, 2023 Filed Dec 14, 2023 16:40 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022552 · form4.xml · nonDerivative · entry 4 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 12,949 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2023 Filed Dec 14, 2023 16:40 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022552 · form4.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,177 Read SEC document |
| November 28, 2023 Filed Nov 28, 2023 22:48 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 642 | $305.10 | $195,874.20 |
DisclosureSEC source: 0001062993-23-021535 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,942 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.05 to $305.13, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 15,000 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 15,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 11 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 16,000 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 16,000 shares, became exercisable in five equal annual installments beginning on September 11, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $119.80 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 10 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 35,000 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 35,000 shares, became exercisable in five equal annual installments beginning on September 10, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 12,024 | $273.00 | $3,282,552.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,360 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 15,000 | $159.32 | $2,389,800.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 12,274 | $273.00 | $3,350,802.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,384 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 16,000 | $139.56 | $2,232,960.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 25,642 | $273.00 | $7,000,266.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,658 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 35,000 | $119.80 | $4,193,000.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2023 Filed Oct 24, 2023 01:10 UTC |
EVRAN SEDATEVP, Global Supply Chain
|
GrantRestricted Stock Units · Derivative | 4,176 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019632 · form4.xml · derivative · entry 1 EVRAN SEDAT · CIK 0001993147 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,176 Underlying: Bio-Rad A Common Stock · 4,176 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 17:06 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017650 · form4.xml · derivative · entry 16 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 2,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 2,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 17:06 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Tax withholdingBio-Rad A Common Stock | 248 | $394.60 | $97,860.80 |
DisclosureSEC source: 0001062993-23-017650 · form4.xml · nonDerivative · entry 10 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,383.7965 Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 17:06 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionBio-Rad A Common Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017650 · form4.xml · nonDerivative · entry 9 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,631.7965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 17:02 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017646 · form4.xml · derivative · entry 16 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 17:02 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Tax withholdingBio-Rad A Common Stock | 298 | $394.60 | $117,590.80 |
DisclosureSEC source: 0001062993-23-017646 · form4.xml · nonDerivative · entry 10 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,584 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.